Skip to content

Alzheimer's Disease Blood Biomarkers Are Affected by Blood Draw Time or Not

Impact of Diurnal Sampling Time Points on Plasma Biomarker Levels in Alzheimer's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121102
Enrollment
Unknown
Registered
2026-03-25
Start date
2026-04-02
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

Observation group:None

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Age range: adults aged 18–40 years; 2.Self-reported health status: No known history of chronic diseases such as cardiovascular, cerebrovascular, metabolic (e.g., diabetes), hepatic, renal, endocrine, or hematologic disorders; no history of fever, infection, trauma, or surgery within the 4 weeks prior to enrollment. 3.Participants should have maintained a regular sleep-wake cycle recently, with no disruptions to circadian rhythms such as frequent night shifts or transmeridian travel. 4.No special dietary regimens (including but not limited to extreme dieting) and no use of any medications (including contraceptives, supplements, etc.) that may affect test results prior to enrollment and throughout the study period. 5.Capable of understanding and signing the informed consent form and committed to strictly adhering to the study protocol (e.g., arriving on time, maintaining fasting status for blood collection, etc.).

Exclusion criteria

Exclusion criteria: 1.Concurrent significant organ failure or dysfunction. 2.History of hemorrhagic or ischemic stroke (including cerebral infarction with an infarct diameter =1 cm). 3.Concurrent cognitive impairment due to any cause, including but not limited to intracranial tumors, metabolic disorders, traumatic brain injury, epilepsy, frontotemporal dementia, or Lewy body dementia; or any other concurrent neuropsychiatric disorders. 4.Rapid cognitive deterioration or stepwise progression, or post-stroke cognitive impairment occurring within 3 months of stroke. 5.Has taken psychoactive medications within the 3 months prior to enrollment. 6.Patients with severe language, hearing, or visual impairment that prevents cooperation.

Design outcomes

Primary

MeasureTime frame
Levels of biomarkers Aß40, Aß42, p-tau181, and p-tau217;

Secondary

MeasureTime frame
Levels of GFAP and NfL;Differences in blood pressure, heart rate, and body temperature at different time points during blood collection;

Countries

China

Contacts

Public ContactBeiyu Zhao

The First Affiliated Hospital of Xi'an Jiaotong University

402936605@qq.com+86 132 2806 2065

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026